Advertisement

Interventional Cardiology in the Cancer Patient

  • Dinu Valentin Balanescu
  • Teodora Donisan
  • Konstantinos Marmagkiolis
  • Cezar IliescuEmail author
Reference work entry

Abstract

In November 2009, the first cardiac catheterization laboratory in a cancer center in the world was opened at The University of Texas MD Anderson Cancer Center. With it surfaced a new field of interventional onco-cardiology. In 2016, an expert consensus from the Society for Cardiovascular Angiography and Interventions issued a landmark document encouraging interventional cardiologists to address the special considerations affiliated with onco-cardiology care. Cancer patients are excluded from most major trials with cardiovascular endpoints, resulting in a lack of guideline-based management. The systemic impact of malignancy determines a pro-inflammatory, prothrombotic state, which in turn leads to accelerated coronary artery disease and an increased risk of acute vascular events. The presence of thrombocytopenia or anemia may discourage invasive management. Conditions unique to this population arise, such as chemotherapy-induced Takotsubo cardiomyopathy or peripheral vascular disease, malignant pericardial effusions, or radiation-induced heart disease. The purpose of this chapter is to highlight the unique issues facing interventional onco-cardiologists and to present the available tools for optimizing cardiovascular care in cancer patients.

Keywords

Cardio-oncology Device-based therapies Endomyocardial biopsy Interventional cardiology Percutaneous coronary intervention Pericardiocentesis Peripheral vascular disease Radiation-induced heart disease Structural valve disease Takotsubo cardiomyopathy 

References

  1. 1.
    Abraham WT, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658–66.  https://doi.org/10.1016/s0140-6736(11)60101-3.CrossRefPubMedGoogle Scholar
  2. 2.
    Adler Y, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC) endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36:2921–64.  https://doi.org/10.1093/eurheartj/ehv318.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Alshiekh-Nasany R, Zidan A, Martinez C. Extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib. Clin Case Rep. 2016;4:1184–6.  https://doi.org/10.1002/ccr3.729.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ameri P, et al. Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Eur J Heart Fail. 2018;20:879–87.  https://doi.org/10.1002/ejhf.1165.CrossRefPubMedGoogle Scholar
  5. 5.
    Amsterdam EA, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;64:e139–228.  https://doi.org/10.1016/j.jacc.2014.09.017.CrossRefPubMedGoogle Scholar
  6. 6.
    Ardehali H, Howard DL, Hariri A, Qasim A, Hare JM, Baughman KL, Kasper EK. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J. 2005;150:459–63.  https://doi.org/10.1016/j.ahj.2004.10.006.CrossRefPubMedGoogle Scholar
  7. 7.
    Ardehali H, Kasper EK, Baughman KL. Diagnostic approach to the patient with cardiomyopathy: whom to biopsy. Am Heart J. 2005;149:7–12.  https://doi.org/10.1016/j.ahj.2004.06.007.CrossRefPubMedGoogle Scholar
  8. 8.
    Armenian SH, et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol. 2016;34:1122–30.  https://doi.org/10.1200/jco.2015.64.0409.CrossRefPubMedGoogle Scholar
  9. 9.
    Armstrong GT, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31:3673–80.  https://doi.org/10.1200/jco.2013.49.3205.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Aronow WS. Management of cardiac hemochromatosis. Arch Med Sci. 2018;14:560–8.  https://doi.org/10.5114/aoms.2017.68729.CrossRefPubMedGoogle Scholar
  11. 11.
    Baibhav B, et al. Role of invasive functional assessment in surgical revascularization of coronary artery disease. Circulation. 2018;137:1731–9.  https://doi.org/10.1161/CIRCULATIONAHA.117.031182.CrossRefPubMedGoogle Scholar
  12. 12.
    Bech GJ, et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. Circulation. 2001;103:2928–34.CrossRefGoogle Scholar
  13. 13.
    Berkovitch A, et al. Favorable short-term and long-term outcomes among patients with prior history of malignancy undergoing transcatheter aortic valve implantation. J Invasive Cardiol. 2018;30:105–9.PubMedGoogle Scholar
  14. 14.
    Braunstein LZ, Cahlon O. Potential morbidity reduction with proton radiation therapy for breast cancer. Semin Radiat Oncol. 2018;28:138–49.  https://doi.org/10.1016/j.semradonc.2017.11.009.CrossRefPubMedGoogle Scholar
  15. 15.
    Brosius FC 3rd, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med. 1981;70:519–30.CrossRefGoogle Scholar
  16. 16.
    Brunetti ND, Santoro F, De Gennaro L, Correale M, Gaglione A, Di Biase M. Drug treatment rates with beta-blockers and ACE-inhibitors/angiotensin receptor blockers and recurrences in takotsubo cardiomyopathy: a meta-regression analysis. Int J Cardiol. 2016;214:340–2.  https://doi.org/10.1016/j.ijcard.2016.03.196.CrossRefPubMedGoogle Scholar
  17. 17.
    Budnik M, Kucharz J, Wiechno P, Demkow T, Kochanowski J, Gorska E, Opolski G. Chemotherapy-induced Takotsubo syndrome. Adv Exp Med Biol. 2018.  https://doi.org/10.1007/5584_2018_222.
  18. 18.
    Burgdorf C, Nef HM, Haghi D, Kurowski V, Radke PW. Tako-tsubo (stress-induced) cardiomyopathy and cancer. Ann Intern Med. 2010;152:830–1.  https://doi.org/10.7326/0003-4819-152-12-201006150-00026.CrossRefPubMedGoogle Scholar
  19. 19.
    Burstein DS, Maude S, Grupp S, Griffis H, Rossano J, Lin K. Cardiac profile of chimeric antigen receptor T cell therapy in children: a single-institution experience. Biol Blood Marrow Transplant. 2018.  https://doi.org/10.1016/j.bbmt.2018.05.014.
  20. 20.
    Butany J, Nair V, Naseemuddin A, Nair GM, Catton C, Yau T. Cardiac tumours: diagnosis and management. Lancet Oncol. 2005;6:219–28.  https://doi.org/10.1016/s1470-2045(05)70093-0.CrossRefPubMedGoogle Scholar
  21. 21.
    Chai-Adisaksopha C, Lam W, Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis. Leuk Lymphoma. 2016;57:1300–10.  https://doi.org/10.3109/10428194.2015.1091929.CrossRefPubMedGoogle Scholar
  22. 22.
    Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol. 2017;70:2536–51.  https://doi.org/10.1016/j.jacc.2017.09.1096.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2. J Am Coll Cardiol. 2017;70:2552–65.  https://doi.org/10.1016/j.jacc.2017.09.1095.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Chen CJ, Sorace BJ, Shakeri A, Park MS, Southerland AM, Worrall BB, Kalani MYS. Tyrosine kinase inhibitor induced rapidly progressive vasculopathy after intracranial stent placement. J Neurointerv Surg. 2018.  https://doi.org/10.1136/neurintsurg-2018-013777.rep.
  25. 25.
    Collet C, et al. Fractional flow reserve derived from computed tomographic angiography in patients with multivessel CAD. J Am Coll Cardiol. 2018;71:2756–69.  https://doi.org/10.1016/j.jacc.2018.02.053.CrossRefPubMedGoogle Scholar
  26. 26.
    Conradi L, et al. Carcinoid heart valve disease: transcatheter pulmonary valve-in-valve implantation in failing biological xenografts. J Heart Valve Dis. 2015;24:110–4.PubMedGoogle Scholar
  27. 27.
    Cooper LT, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007;50:1914–31.  https://doi.org/10.1016/j.jacc.2007.09.008.CrossRefPubMedGoogle Scholar
  28. 28.
    Cooper LT Jr. Role of left ventricular biopsy in the management of heart disease. Circulation. 2013;128:1492–4.  https://doi.org/10.1161/circulationaha.113.005395.CrossRefPubMedGoogle Scholar
  29. 29.
    Courtis J, et al. Usefulness of coronary fractional flow reserve measurements in guiding clinical decisions in intermediate or equivocal left main coronary stenoses. Am J Cardiol. 2009;103:943–9.  https://doi.org/10.1016/j.amjcard.2008.11.054.CrossRefPubMedGoogle Scholar
  30. 30.
    Cuomo JR, Javaheri SP, Sharma GK, Kapoor D, Berman AE, Weintraub NL. How to prevent and manage radiation-induced coronary artery disease. Heart. 2018.  https://doi.org/10.1136/heartjnl-2017-312123.
  31. 31.
    Damrongwatanasuk R, Fradley MG. Cardiovascular complications of targeted therapies for chronic myeloid leukemia. Curr Treat Options Cardiovasc Med. 2017;19:24.  https://doi.org/10.1007/s11936-017-0524-8.CrossRefPubMedGoogle Scholar
  32. 32.
    Darby SC, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76:656–65.  https://doi.org/10.1016/j.ijrobp.2009.09.064.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Darby SC, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–98.  https://doi.org/10.1056/NEJMoa1209825.CrossRefPubMedGoogle Scholar
  34. 34.
    Davies JE, et al. Use of the instantaneous wave-free ratio or fractional flow reserve in PCI. N Engl J Med. 2017;376:1824–34.  https://doi.org/10.1056/NEJMoa1700445.CrossRefPubMedGoogle Scholar
  35. 35.
    De Bruyne B, et al. Coronary flow reserve calculated from pressure measurements in humans. Validation with positron emission tomography. Circulation. 1994;89:1013–22.CrossRefGoogle Scholar
  36. 36.
    Donis N, Oury C, Moonen M, Lancellotti P. Treating cardiovascular complications of radiotherapy: a role for new pharmacotherapies. Expert Opin Pharmacother. 2018;19:431–42.  https://doi.org/10.1080/14656566.2018.1446080.CrossRefPubMedGoogle Scholar
  37. 37.
    Donnellan E, et al. Long-term outcomes of patients with mediastinal radiation-associated severe aortic stenosis and subsequent surgical aortic valve replacement: a matched cohort study. J Am Heart Assoc. 2017;6.  https://doi.org/10.1161/jaha.116.005396.
  38. 38.
    Dorresteijn LD, et al. Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. J Clin Oncol. 2002;20:282–8.  https://doi.org/10.1200/jco.2002.20.1.282.CrossRefPubMedGoogle Scholar
  39. 39.
    El Haddad D, Iliescu C, Yusuf SW, William WN Jr, Khair TH, Song J, Mouhayar EN. Outcomes of cancer patients undergoing percutaneous pericardiocentesis for pericardial effusion. J Am Coll Cardiol. 2015;66:1119–28.  https://doi.org/10.1016/j.jacc.2015.06.1332.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    El-Sayed AM, Brinjikji W, Salka S. Demographic and co-morbid predictors of stress (takotsubo) cardiomyopathy. Am J Cardiol. 2012;110:1368–72.  https://doi.org/10.1016/j.amjcard.2012.06.041.CrossRefPubMedGoogle Scholar
  41. 41.
    Escher F, et al. Analysis of endomyocardial biopsies in suspected myocarditis – diagnostic value of left versus right ventricular biopsy. Int J Cardiol. 2014;177:76–8.  https://doi.org/10.1016/j.ijcard.2014.09.071.CrossRefPubMedGoogle Scholar
  42. 42.
    Faggiano P, et al. Prevalence of comorbidities and associated cardiac diseases in patients with valve aortic stenosis. Potential implications for the decision-making process. Int J Cardiol. 2012;159:94–9.  https://doi.org/10.1016/j.ijcard.2011.02.026.CrossRefPubMedGoogle Scholar
  43. 43.
    Feldman D, et al. The 2013 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013;32:157–87.  https://doi.org/10.1016/j.healun.2012.09.013.CrossRefPubMedGoogle Scholar
  44. 44.
    Fender EA, et al. Coronary artery bypass grafting in patients treated with thoracic radiation: a case-control study. Open Heart. 2018;5:e000766.  https://doi.org/10.1136/openhrt-2017-000766.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Fidler MM, et al. Population-based long-term cardiac-specific mortality among 34 489 five-year survivors of childhood cancer in Great Britain. Circulation. 2017;135:951–63.  https://doi.org/10.1161/circulationaha.116.024811.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Fleming RM, Kirkeeide RL, Smalling RW, Gould KL. Patterns in visual interpretation of coronary arteriograms as detected by quantitative coronary arteriography. J Am Coll Cardiol. 1991;18:945–51.CrossRefGoogle Scholar
  47. 47.
    Fowkes FG, et al. Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197–208.  https://doi.org/10.1001/jama.300.2.197.CrossRefPubMedGoogle Scholar
  48. 48.
    From AM, Maleszewski JJ, Rihal CS. Current status of endomyocardial biopsy. Mayo Clin Proc. 2011;86:1095–102.  https://doi.org/10.4065/mcp.2011.0296.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Gernaat SAM, et al. Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat. 2017;164:537–55.  https://doi.org/10.1007/s10549-017-4282-9.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Ghosh AK, Crake T, Manisty C, Westwood M. Pericardial disease in cancer patients. Curr Treat Options Cardiovasc Med. 2018;20:60.  https://doi.org/10.1007/s11936-018-0654-7.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Givertz MM, et al. Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2017;70:1875–86.  https://doi.org/10.1016/j.jacc.2017.08.010.CrossRefPubMedGoogle Scholar
  52. 52.
    Giza DE, et al. Stress-induced cardiomyopathy in cancer patients. Am J Cardiol. 2017;120:2284–8.  https://doi.org/10.1016/j.amjcard.2017.09.009.CrossRefPubMedGoogle Scholar
  53. 53.
    Gonzalo N, et al. Morphometric assessment of coronary stenosis relevance with optical coherence tomography: a comparison with fractional flow reserve and intravascular ultrasound. J Am Coll Cardiol. 2012;59:1080–9.  https://doi.org/10.1016/j.jacc.2011.09.078.CrossRefPubMedGoogle Scholar
  54. 54.
    Gornik HL, Gerhard-Herman M, Beckman JA. Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol. 2005;23:5211–6.  https://doi.org/10.1200/jco.2005.00.745.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Gotberg M, et al. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. N Engl J Med. 2017;376:1813–23.  https://doi.org/10.1056/NEJMoa1616540.CrossRefPubMedGoogle Scholar
  56. 56.
    Guddati AK, Joy PS, Kumar G. Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period. J Cancer Res Clin Oncol. 2016;142:471–9.  https://doi.org/10.1007/s00432-015-2056-5.CrossRefPubMedGoogle Scholar
  57. 57.
    Hamirani Y, Fanous I, Kramer CM, Wong A, Salerno M, Dillon P. Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study. Med Oncol. 2016;33:82.  https://doi.org/10.1007/s12032-016-0797-x.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA. 1993;270:1949–55.CrossRefGoogle Scholar
  59. 59.
    Harwani N, Chukwu E, Alvarez M, Thohan V. Comparison of brachial vein versus internal jugular vein approach for access to the right side of the heart with or without myocardial biopsy. Am J Cardiol. 2015;116:740–3.  https://doi.org/10.1016/j.amjcard.2015.05.044.CrossRefPubMedGoogle Scholar
  60. 60.
    Hassan SA, Banchs J, Iliescu C, Dasari A, Lopez-Mattei J, Yusuf SW. Carcinoid Heart Dis Heart. 2017;103:1488–95.  https://doi.org/10.1136/heartjnl-2017-311261.CrossRefGoogle Scholar
  61. 61.
    Hess CN et al. Relationship between cancer and cardiovascular outcomes following percutaneous coronary intervention. J Am Heart Assoc. 2015;4.  https://doi.org/10.1161/jaha.115.001779.
  62. 62.
    Hudzik B, et al. Malignant tumors of the heart. Cancer Epidemiol. 2015;39:665–72.  https://doi.org/10.1016/j.canep.2015.07.007.CrossRefPubMedGoogle Scholar
  63. 63.
    Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831–7.  https://doi.org/10.1001/jama.290.21.2831.CrossRefPubMedGoogle Scholar
  64. 64.
    Iannaccone M, et al. Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy. Eur Heart J Acute Cardiovasc Care. 2017.  https://doi.org/10.1177/2048872617706501.
  65. 65.
    Iliescu C, et al. Optical coherence tomography-guided antiplatelet therapy in patients with coronary artery disease and cancer: the protect-oct registry. J Am Coll Cardiol. 2013;61.  https://doi.org/10.1016/S0735-1097(13)61128-6.
  66. 66.
    Iliescu C, Khair T, Marmagkiolis K, Iliescu G, Durand JB. Echocardiography and fluoroscopy-guided pericardiocentesis for cancer patients with cardiac tamponade and thrombocytopenia. J Am Coll Cardiol. 2016;68:771–3.  https://doi.org/10.1016/j.jacc.2016.05.068.CrossRefPubMedGoogle Scholar
  67. 67.
    Iliescu CA, et al. SCAI Expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista). Catheter Cardiovasc Interv. 2016.  https://doi.org/10.1002/ccd.26379.
  68. 68.
    Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. J Am Coll Cardiol. 2013;61:2319–28.  https://doi.org/10.1016/j.jacc.2013.01.090.CrossRefPubMedGoogle Scholar
  69. 69.
    Johnson NP, Kirkeeide RL, Gould KL. Coronary anatomy to predict physiology: fundamental limits. Circ Cardiovasc Imaging. 2013;6:817–32.  https://doi.org/10.1161/circimaging.113.000373.CrossRefPubMedGoogle Scholar
  70. 70.
    Jurado J, Thompson PD. Prevention of coronary artery disease in cancer patients. Pediatr Blood Cancer. 2005;44:620–4.  https://doi.org/10.1002/pbc.20349.CrossRefPubMedGoogle Scholar
  71. 71.
    Jurado JA, Bashir R, Burket MW. Radiation-induced peripheral artery disease. Catheter Cardiovasc Interv. 2008;72:563–8.  https://doi.org/10.1002/ccd.21681.CrossRefPubMedGoogle Scholar
  72. 72.
    Khan T, et al. The value of endomyocardial biopsy in diagnosis and guiding therapy. Pathology. 2017;49:750–6.  https://doi.org/10.1016/j.pathol.2017.08.004.CrossRefPubMedGoogle Scholar
  73. 73.
    Kim TD, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013;27:1316–21.  https://doi.org/10.1038/leu.2013.70.CrossRefPubMedGoogle Scholar
  74. 74.
    Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133:1104–14.  https://doi.org/10.1161/circulationaha.115.020406.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Levenback C, Burke TW, Rubin SC, Curtin JP, Wharton JT. Arterial occlusion complicating treatment of gynecologic cancer: a case series. Gynecol Oncol. 1996;63:40–6.  https://doi.org/10.1006/gyno.1996.0275.CrossRefPubMedGoogle Scholar
  76. 76.
    Levine GN, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016;134:e123–55.  https://doi.org/10.1161/cir.0000000000000404.CrossRefPubMedGoogle Scholar
  77. 77.
    Li J, et al. Long-term outcomes of fractional flow reserve-guided vs. angiography-guided percutaneous coronary intervention in contemporary practice. Eur Heart J. 2013;34:1375–83.  https://doi.org/10.1093/eurheartj/eht005.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Liang JJ, Sio TT, Slusser JP, Lennon RJ, Miller RC, Sandhu G, Prasad A. Outcomes after percutaneous coronary intervention with stents in patients treated with thoracic external beam radiation for cancer. JACC Cardiovasc Interv. 2014;7:1412–20.  https://doi.org/10.1016/j.jcin.2014.05.035.CrossRefPubMedGoogle Scholar
  79. 79.
    Liu VY, et al. Interventional cardio-oncology: adding a new dimension to the cardio-oncology field. Front Cardiovasc Med. 2018;5:48.  https://doi.org/10.3389/fcvm.2018.00048.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Loh JP, Barbash IM, Waksman R. Overview of the 2011 Food and Drug Administration circulatory system devices panel of the medical devices advisory committee meeting on the CardioMEMS Champion heart failure monitoring system. J Am Coll Cardiol. 2013;61:1571–6.  https://doi.org/10.1016/j.jacc.2012.08.1035.CrossRefPubMedGoogle Scholar
  81. 81.
    Lorusso R, et al. Cardiac surgery in adult patients with remitted or active malignancies: a review of preoperative screening, surgical management and short- and long-term postoperative results. Eur J Cardiothorac Surg. 2018;54:10–8.  https://doi.org/10.1093/ejcts/ezy019.CrossRefPubMedGoogle Scholar
  82. 82.
    Lund LH, Braunschweig F, Benson L, Stahlberg M, Dahlstrom U, Linde C. Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry. Eur J Heart Fail. 2017;19:1270–9.  https://doi.org/10.1002/ejhf.781.CrossRefPubMedGoogle Scholar
  83. 83.
    Mangner N, et al. Impact of active cancer disease on the outcome of patients undergoing transcatheter aortic valve replacement. J Interv Cardiol. 2018;31:188–96.  https://doi.org/10.1111/joic.12458.CrossRefPubMedGoogle Scholar
  84. 84.
    Miller KD, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271–89.  https://doi.org/10.3322/caac.21349.CrossRefGoogle Scholar
  85. 85.
    Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33:4210–8.  https://doi.org/10.1200/jco.2015.62.4718.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391:933.  https://doi.org/10.1016/s0140-6736(18)30533-6.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Munoz E, et al. Takotsubo stress cardiomyopathy: “good news” in cancer patients? J Am Coll Cardiol. 2016;68:1143–4.  https://doi.org/10.1016/j.jacc.2016.06.027.CrossRefPubMedGoogle Scholar
  88. 88.
    Nadruz W Jr, et al. Cardiovascular phenotype and prognosis of patients with heart failure induced by cancer therapy. Heart. 2018.  https://doi.org/10.1136/heartjnl-2018-313234.
  89. 89.
    Nam CW, et al. Functional SYNTAX score for risk assessment in multivessel coronary artery disease. J Am Coll Cardiol. 2011;58:1211–8.  https://doi.org/10.1016/j.jacc.2011.06.020.CrossRefPubMedGoogle Scholar
  90. 90.
    O'Gara PT, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013;127:e362–425.  https://doi.org/10.1161/CIR.0b013e3182742cf6.CrossRefPubMedGoogle Scholar
  91. 91.
    Oliveira GH, Qattan MY, Al-Kindi S, Park SJ. Advanced heart failure therapies for patients with chemotherapy-induced cardiomyopathy. Circ Heart Fail. 2014;7:1050–8.  https://doi.org/10.1161/circheartfailure.114.001292.CrossRefPubMedGoogle Scholar
  92. 92.
    Oner A, et al. Previous malignancy is an independent predictor of follow-up mortality after percutaneous treatment of mitral valve regurgitation by means of MitraClip. Cardiovasc Ther. 2017;35.  https://doi.org/10.1111/1755-5922.12239.
  93. 93.
    Ozaki T, Nakamura H, Izutsu N, Masaie H, Ishikawa J, Kinoshita M. Intracranial stenting for nilotinib treatment-associated cerebrovascular stenosis in chronic myeloid leukemia. Interv Neuroradiol. 2017;23:527–30.  https://doi.org/10.1177/1591019917710810.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Palaskas N, et al. Evaluation and management of cardiac tumors. Curr Treat Options Cardiovasc Med. 2018;20:29.  https://doi.org/10.1007/s11936-018-0625-z.CrossRefPubMedGoogle Scholar
  95. 95.
    Park SJ, et al. Intravascular ultrasound-derived minimal lumen area criteria for functionally significant left main coronary artery stenosis. JACC Cardiovasc Interv. 2014;7:868–74.  https://doi.org/10.1016/j.jcin.2014.02.015.CrossRefPubMedGoogle Scholar
  96. 96.
    Patel MR, Calhoon JH, Dehmer GJ, Grantham JA, Maddox TM, Maron DJ, Smith PK. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2017;69:2212–41.  https://doi.org/10.1016/j.jacc.2017.02.001.CrossRefPubMedGoogle Scholar
  97. 97.
    Pijls NH, De Bruyne B, Bech GJ, Liistro F, Heyndrickx GR, Bonnier HJ, Koolen JJ. Coronary pressure measurement to assess the hemodynamic significance of serial stenoses within one coronary artery: validation in humans. Circulation. 2000;102:2371–7.CrossRefGoogle Scholar
  98. 98.
    Pijls NH, et al. Coronary pressure measurement after stenting predicts adverse events at follow-up: a multicenter registry. Circulation. 2002;105:2950–4.CrossRefGoogle Scholar
  99. 99.
    Pijls NH, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER study. J Am Coll Cardiol. 2007;49:2105–11.  https://doi.org/10.1016/j.jacc.2007.01.087.CrossRefPubMedGoogle Scholar
  100. 100.
    Ponikowski P, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.  https://doi.org/10.1002/ejhf.592.CrossRefPubMedGoogle Scholar
  101. 101.
    Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J. 2008;155:408–17.  https://doi.org/10.1016/j.ahj.2007.11.008.CrossRefPubMedGoogle Scholar
  102. 102.
    Raghunathan D, Khilji MI, Hassan SA, Yusuf SW. Radiation-induced cardiovascular disease. Curr Atheroscler Rep. 2017;19:22.  https://doi.org/10.1007/s11883-017-0658-x.CrossRefPubMedGoogle Scholar
  103. 103.
    Reed GW, Masri A, Griffin BP, Kapadia SR, Ellis SG, Desai MY. Long-term mortality in patients with radiation-associated coronary artery disease treated with percutaneous coronary intervention. Circ Cardiovasc Interv. 2016;9.  https://doi.org/10.1161/circinterventions.115.003483.
  104. 104.
    Roof L, Coker WJ, Lazarchick J, Kang Y. Senile transthyretin cardiac amyloidosis in patients with plasma cell dyscrasias: importance of cardiac biopsy for making the correct diagnosis. Aperito J Cell Mol Biol. 2014;1:102.PubMedPubMedCentralGoogle Scholar
  105. 105.
    Sagrista-Sauleda J, Merce J, Permanyer-Miralda G, Soler-Soler J. Clinical clues to the causes of large pericardial effusions. Am J Med. 2000;109:95–101.CrossRefGoogle Scholar
  106. 106.
    Saka B, et al. Bilateral renal artery stenosis after abdominal radiotherapy for Hodgkin’s disease. Int J Clin Pract. 2003;57:247–8.PubMedGoogle Scholar
  107. 107.
    Schaar JA, van der Steen AF, Mastik F, Baldewsing RA, Serruys PW. Intravascular palpography for vulnerable plaque assessment. J Am Coll Cardiol. 2006;47:C86–91.  https://doi.org/10.1016/j.jacc.2006.01.035.CrossRefPubMedGoogle Scholar
  108. 108.
    Schaufele TG, et al. Transradial left ventricular endomyocardial biopsy: assessment of safety and efficacy. Clin Res Cardiol. 2015;104:773–81.  https://doi.org/10.1007/s00392-015-0844-1.CrossRefPubMedGoogle Scholar
  109. 109.
    Skinner M, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85–93.CrossRefGoogle Scholar
  110. 110.
    Slawek S, et al. Endomyocardial biopsy via the femoral access – still safe and valuable diagnostic tool. BMC Cardiovasc Disord. 2016;16:222.  https://doi.org/10.1186/s12872-016-0406-0.CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Spetz J, Moslehi J, Sarosiek K. Radiation-induced cardiovascular toxicity: mechanisms, prevention, and treatment. Curr Treat Options Cardiovasc Med. 2018;20:31.  https://doi.org/10.1007/s11936-018-0627-x.CrossRefPubMedGoogle Scholar
  112. 112.
    Stewart FA, Heeneman S, Te Poele J, Kruse J, Russell NS, Gijbels M, Daemen M. Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE-/- mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage. Am J Pathol. 2006;168:649–58.  https://doi.org/10.2353/ajpath.2006.050409.CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Stiermaier T, et al. Long-term excess mortality in takotsubo cardiomyopathy: predictors, causes and clinical consequences. Eur J Heart Fail. 2016;18:650–6.  https://doi.org/10.1002/ejhf.494.CrossRefPubMedGoogle Scholar
  114. 114.
    Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34:1102–11.  https://doi.org/10.1093/eurheartj/ehs181.CrossRefPubMedGoogle Scholar
  115. 115.
    Suzuki S, Usui A, Yoshida K, Matsuura A, Ichihara T, Ueda Y. Effect of cardiopulmonary bypass on cancer prognosis. Asian Cardiovasc Thorac Ann. 2010;18:536–40.  https://doi.org/10.1177/0218492310388453.CrossRefPubMedGoogle Scholar
  116. 116.
    Takami Y, et al. Recovery from anthracycline-induced cardiomyopathy with biventricular assist and valve repairs: a case report and literature review. Int J Artif Organs. 2018;41:413–7.  https://doi.org/10.1177/0391398818772497.CrossRefPubMedGoogle Scholar
  117. 117.
    Templin C, et al. Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373:929–38.  https://doi.org/10.1056/NEJMoa1406761.CrossRefPubMedGoogle Scholar
  118. 118.
    Thiene G, Bruneval P, Veinot J, Leone O. Diagnostic use of the endomyocardial biopsy: a consensus statement. Virchows Arch. 2013;463:1–5.  https://doi.org/10.1007/s00428-013-1430-4.CrossRefPubMedGoogle Scholar
  119. 119.
    Timmis A, Roobottom CA. National Institute for health and care excellence updates the stable chest pain guideline with radical changes to the diagnostic paradigm. Heart. 2017;103:982–6.  https://doi.org/10.1136/heartjnl-2015-308341.CrossRefPubMedGoogle Scholar
  120. 120.
    Ting AC, Cheng SW, Yeung KM, Cheng PW, Lui WM, Ho P, Tso WK. Carotid stenting for radiation-induced extracranial carotid artery occlusive disease: efficacy and midterm outcomes. J Endovasc Ther. 2004;11:53–9.  https://doi.org/10.1177/152660280401100107.CrossRefPubMedGoogle Scholar
  121. 121.
    Tonino PA, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213–24.  https://doi.org/10.1056/NEJMoa0807611.CrossRefPubMedGoogle Scholar
  122. 122.
    Tornvall P, Collste O, Ehrenborg E, Jarnbert-Petterson H. A case-control study of risk markers and mortality in Takotsubo stress cardiomyopathy. J Am Coll Cardiol. 2016;67:1931–6.  https://doi.org/10.1016/j.jacc.2016.02.029.CrossRefPubMedGoogle Scholar
  123. 123.
    Toscano G, Bortolami A, Gerosa G. Is it possible to process to endomyocardial biopsy with right internal jugular occlusion without X-ray? Transpl Int. 2014;27:e94–5.  https://doi.org/10.1111/tri.12352.CrossRefPubMedGoogle Scholar
  124. 124.
    Toscano G, Gambino A, Bagozzi L, Guariento A, D’Amico G, Fedrigo M, Gerosa G. Endomyocardial biopsy under echocardiographic monitoring. Multimed Man Cardiothorac Surg. 2016.  https://doi.org/10.1093/mmcts/mmw006.
  125. 125.
    Vakamudi S, Ho N, Cremer PC. Pericardial effusions: causes, diagnosis, and management. Prog Cardiovasc Dis. 2017;59:380–8.  https://doi.org/10.1016/j.pcad.2016.12.009.CrossRefPubMedGoogle Scholar
  126. 126.
    Van Belle E, et al. Outcome impact of coronary revascularization strategy reclassification with fractional flow reserve at time of diagnostic angiography: insights from a large French multicenter fractional flow reserve registry. Circulation. 2014;129:173–85.  https://doi.org/10.1161/circulationaha.113.006646.CrossRefPubMedGoogle Scholar
  127. 127.
    Velders MA, et al. Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. Am J Cardiol. 2013;112:1867–72.  https://doi.org/10.1016/j.amjcard.2013.08.019.CrossRefPubMedGoogle Scholar
  128. 128.
    Viganego F, Singh R, Fradley MG. Arrhythmias and other electrophysiology issues in cancer patients receiving chemotherapy or radiation. Curr Cardiol Rep. 2016;18:52.  https://doi.org/10.1007/s11886-016-0730-0.CrossRefPubMedGoogle Scholar
  129. 129.
    Waksman R, et al. FIRST: fractional flow reserve and intravascular ultrasound relationship study. J Am Coll Cardiol. 2013;61:917–23.  https://doi.org/10.1016/j.jacc.2012.12.012.CrossRefPubMedGoogle Scholar
  130. 130.
    Watanabe Y, et al. Comparison of results of transcatheter aortic valve implantation in patients with versus without active cancer. Am J Cardiol. 2016;118:572–7.  https://doi.org/10.1016/j.amjcard.2016.05.052.CrossRefPubMedGoogle Scholar
  131. 131.
    Windecker S, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention. 2015;10:1024–94.  https://doi.org/10.4244/eijy14m09_01.CrossRefPubMedGoogle Scholar
  132. 132.
    Wong RC, Abrahams Z, Hanna M, Pangrace J, Gonzalez-Stawinski G, Starling R, Taylor D. Tricuspid regurgitation after cardiac transplantation: an old problem revisited. J Heart Lung Transplant. 2008;27:247–52.  https://doi.org/10.1016/j.healun.2007.12.011.CrossRefPubMedGoogle Scholar
  133. 133.
    Wu W, et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study. Circulation. 2013;127:1476–85.  https://doi.org/10.1161/circulationaha.113.001435.CrossRefPubMedGoogle Scholar
  134. 134.
    Yang EH, Watson KE, Herrmann J. Should vascular effects of newer treatments be addressed more completely? Future Oncol. 2015;11:1995–8.  https://doi.org/10.2217/fon.15.119.CrossRefPubMedGoogle Scholar
  135. 135.
    Yilmaz A, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation. 2010;122:900–9.  https://doi.org/10.1161/circulationaha.109.924167.CrossRefPubMedGoogle Scholar
  136. 136.
    Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol. 2012;35:443–50.  https://doi.org/10.1002/clc.22007.CrossRefPubMedPubMedCentralGoogle Scholar
  137. 137.
    Yusuf SW, Sarfaraz A, Durand JB, Swafford J, Daher IN. Management and outcomes of severe aortic stenosis in cancer patients. Am Heart J. 2011;161:1125–32.  https://doi.org/10.1016/j.ahj.2011.03.013.CrossRefPubMedGoogle Scholar
  138. 138.
    Zamorano JL, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–801.  https://doi.org/10.1093/eurheartj/ehw211.CrossRefPubMedGoogle Scholar
  139. 139.
    Zimmermann FM, et al. Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial. Eur Heart J. 2015;36:3182–8.  https://doi.org/10.1093/eurheartj/ehv452.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Dinu Valentin Balanescu
    • 1
  • Teodora Donisan
    • 1
  • Konstantinos Marmagkiolis
    • 2
  • Cezar Iliescu
    • 1
    Email author
  1. 1.Department of CardiologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Florida Hospital Pepin Heart InstituteTampaUSA

Personalised recommendations